LivaNova climbs on high chance of trial success for sleep apnea device

Livanova

20/03/2024 14:30

** U.S.-listed shares of U.K.-based medical device maker
LivaNova  LIVN.O  rise 7.8% to $54.25 
    ** Co says its nerve stimulator device showed more than
97.5% probability of successfully meeting the main goal in a
trial where it is being evaluated in patients with obstructive
sleep apnea (OSA)
    ** Co has enrolled 90 patients for the trial and will
evaluate the patients' response to the device with long-term
follow-up visits
    ** OSA occurs when the throat muscles relax and block the
airway during sleep
    ** Up to last close, stock was up 15.4% in the last 12
months

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))